2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MAP4K
  5. MAP4K Inhibitor

MAP4K Inhibitor

MAP4K Isoform Comparison

MAP4K Inhibitors (68):

Cat. No. Product Name Effect Purity
  • HY-100830
    NCB-0846
    		Inhibitor 99.61%
    NCB-0846 is an orally available TNIK inhibitor with an IC50 of 21 nM.
  • HY-100343
    GNE-495
    		Inhibitor 99.40%
    GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
  • HY-111754
    DMX-5804
    		Inhibitor 99.83%
    DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.
  • HY-15434
    NG25
    		Inhibitor 99.35%
    NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.
  • HY-19562
    PF-06260933
    		Inhibitor 99.67%
    PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
  • HY-149056A
    (3S,4R)-GNE-6893
    		Inhibitor 99.49%
    (3S,4R)-GNE-6893 is a potent and orally active HPK1 inhibitor. (3S,4R)-GNE-6893 can be used in research of cancer.
  • HY-159643
    NDI-101150
    		Inhibitor
    NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor. NDI-101150 enhances T cell activation and inhibits tumor growth.
  • HY-138568
    HPK1-IN-3
    		Inhibitor 99.32%
    HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs).
  • HY-124745
    KY-05009
    		Inhibitor 99.24%
    KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity.
  • HY-138742
    HPK1-IN-7
    		Inhibitor 99.33%
    HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.
  • HY-135892
    GNE-1858
    		Inhibitor 99.42%
    GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC50s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively.
  • HY-157149
    DS21150768
    		Inhibitor 99.26%
    DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects.
  • HY-148847
    HPK1-IN-32
    		Inhibitor 98.12%
    HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases.
  • HY-144088
    ZYF0033
    		Inhibitor 98.86%
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a+ CD8+ T Cells, PD-1+CD8+ T Cells, TIM-3+CD8+ T Cells LAG3< sup>+CD8+ T Cellular immersion decreases.
  • HY-125012
    MAP4K4-IN-3
    		Inhibitor 99.15%
    MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent.
  • HY-U00428A
    GNE 220 hydrochloride
    		Inhibitor 98.22%
    GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM.
  • HY-160623
    INS018 055
    		Inhibitor 99.38%
    INS018 055 (compound 112) is a TNIK and MAP4K4 inhibitor with IC50 values of 12-120, 12-120 nM, respectively.
  • HY-146231A
    SS47 TFA
    		Inhibitor 99.88%
    SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-123714
    TL4-12
    		Inhibitor 99.82%
    TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC50=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM).
  • HY-77251
    TAK1/MAP4K2 inhibitor 1
    		Inhibitor 99.90%
    TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.